Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality-Reference-Cited by-同舟云学术

Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality

Published:2024-02-26 Issue:6 Volume:10 Page:1156-1166
ISSN:2374-7943
Container-title:ACS Central Science
language:en
Short-container-title:ACS Cent. Sci.

Author:

Li Zhengnian¹^ORCID,Jiang Jie²³⁴^ORCID,Ficarro Scott B.⁵⁶⁷,Beyett Tyler S.⁵⁸^ORCID,To Ciric²³⁴,Tavares Isidoro⁵⁶,Zhu Yingde⁵,Li Jiaqi²³⁴,Eck Michael J.⁵⁸,Jänne Pasi A.²³⁴,Marto Jarrod A.⁵⁶⁷^ORCID,Zhang Tinghu¹^ORCID,Che Jianwei⁵,Gray Nathanael S.¹^ORCID

Affiliation:

1. Department of Chemical and Systems Biology, Stanford Cancer Institute, ChEM-H, Stanford University, Stanford, California 94305, United States

2. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States

3. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States

4. Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, United States

5. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States

6. Blais Proteomics Center, Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States

7. Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02215, United States

8. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States

Funder

National Cancer Institute

National Institutes of Health

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acscentsci.3c01245

Reference45 articles.

1. The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication

2. The druggable genome

3. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

4. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

5. Reactive-cysteine profiling for drug discovery

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Targeting of Protein Complexes with Molecular COUPLrs;2024-07-18

2. Covalent Inhibitors: To Infinity and Beyond;Journal of Medicinal Chemistry;2024-06-24